Skip to main content

BFRI

Biofrontera Inc.
$0.95 -0.07 (-7.25%)
1 Down Day

Price & Indicators

50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.95 Open$1.01 Day$0.92–1.03 52W$0.56–1.19 Avg vol 30d204K Short int56K · 1.0d Short vol36% Last earningsMay 14, 2026 DataOct 2021–Jun 2026 Filing10-Q · May 14
Equibles Rating blended score
Overall
Buy
Technical · trend & momentum Buy
+ Price vs 200-day avg · +3% above
Sentiment · smart money Neutral
+ Short interest · 0.44% of float · ▼ -19.2% MoM · 1.0 days cover
Fundamentals Strong
+ Revenue growth · +19% Y/Y

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Key facts
Market Cap
$12.11M
Shares
12,803,344
CIK
1858685
CUSIP
09077D209
Investor Relations
Investor relations
Up next
Next earnings call
Aug 13, 2026 Est · unconfirmed · in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 2
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      +3% above Bullish
      Price vs 50-day avg
      −3% below Neutral
      RSI (14)
      49 · neutral Neutral
      MACD trend
      positive Bullish
      52-week position
      62% · mid-range Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Distributing
      -14% holders QoQ · +2 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      0.44% of float · ▼ -19.2% MoM · 1.0 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      12 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $1 · 62% 52-wk high $1
      vs 200-day avg +3% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP -$3.6M Q1 2026
      Adjusted EBITDA margin non-GAAP -35.3% first quarter of 2026
      Ameluz units sold growth 16% first quarter of 2026
      Cash used in operations $70K Q1 2026
      Operating cash balance $6.3M as of March 31, 2026

      Figures exactly as the company stated them · period links open the stating release · YoY needs the prior-year figure on file

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BFRI
      Biofrontera Inc.
      this stock
      $12.11M +66.0% +19.0% 0.4%
      GALDY
      Galderma Group AG/ADR
      $53.33B +9.7% 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      $50.65B +2.8% 0.3%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      $45.13B 0.0%
      HLN
      Haleon plc
      $41.35B -7.7% 0.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      12
      % held
      18.7%
      Net QoQ
      +54.2K sh
      Top holder
      Rosalind Advisors, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      5
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      56.1K
      Days to cover
      1.0d
      Change
      -13.3K sh
      View
      Short Volume
      Short vol %
      36%
      As of
      Jul 1, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      20.0K
      Value
      $15.6K
      As of
      May 22, 2026
      View
      Off-Exchange
      Off-exchange %
      62.9%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $41.7M
      Net income (FY)
      $-10.5M
      EPS diluted
      $-1.04
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 17, 2026
      This year
      11
      View
      Exempt Offerings
      Offering
      $11.0M
      Filed
      Jul 11, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 14, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      BFRI -8.2% -0.9% +19.0% +6.8% +66.0%
      SPY +1.8% -1.6% +7.9% -1.3% +9.5%
      vs SPY -10.0% +0.7% +11.1% +8.1% +56.5%